Your browser is no longer supported. Please, upgrade your browser.
iBio, Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own0.10% Shs Outstand216.01M Perf Week14.29%
Market Cap394.98M Forward P/E- EPS next Y-0.21 Insider Trans-99.23% Shs Float181.60M Perf Month43.09%
Income-41.30M PEG- EPS next Q-0.04 Inst Own8.00% Short Float6.63% Perf Quarter-6.88%
Sales1.90M P/S207.88 EPS this Y35.40% Inst Trans5.77% Short Ratio1.02 Perf Half Y-69.50%
Book/sh0.49 P/B3.59 EPS next Y-10.50% ROA-57.00% Target Price2.00 Perf Year473.66%
Cash/sh0.37 P/C4.73 EPS next 5Y- ROE-118.00% 52W Range0.23 - 7.45 Perf YTD67.62%
Dividend- P/FCF- EPS past 5Y8.00% ROI-15.60% 52W High-76.38% Beta-6.06
Dividend %- Quick Ratio16.70 Sales past 5Y-2.40% Gross Margin- 52W Low664.55% ATR0.13
Employees43 Current Ratio16.80 Sales Q/Q300.00% Oper. Margin- RSI (14)67.70 Volatility7.76% 8.68%
OptionableYes Debt/Eq0.41 EPS Q/Q77.40% Profit Margin- Rel Volume4.32 Prev Close1.46
ShortableYes LT Debt/Eq0.40 EarningsNov 16 BMO Payout- Avg Volume11.78M Price1.76
Recom2.00 SMA2037.61% SMA5026.31% SMA200-8.80% Volume50,852,079 Change20.55%
Jan-22-21Initiated Cantor Fitzgerald Overweight $3
Jun-26-20Initiated Alliance Global Partners Buy $2.55
Jan-22-21 02:02PM  
Dec-28-20 07:30AM  
Dec-10-20 04:30PM  
Dec-08-20 08:55AM  
Dec-07-20 04:01PM  
Dec-04-20 11:40AM  
Dec-01-20 04:30PM  
Nov-27-20 07:10PM  
Nov-25-20 12:12PM  
Nov-24-20 07:30AM  
Nov-20-20 10:13AM  
Nov-16-20 04:05PM  
Nov-15-20 06:14AM  
Nov-13-20 10:48AM  
Nov-12-20 08:00AM  
Nov-05-20 04:30PM  
Nov-03-20 07:30AM  
Oct-29-20 06:29AM  
Oct-15-20 04:05PM  
Oct-14-20 04:05PM  
Oct-13-20 04:05PM  
Oct-05-20 07:30AM  
Oct-02-20 01:04PM  
Sep-21-20 02:55PM  
Sep-18-20 01:58PM  
Sep-09-20 11:58AM  
Sep-03-20 03:29PM  
Aug-28-20 01:58PM  
Aug-24-20 08:42AM  
Aug-19-20 12:52PM  
Aug-14-20 04:55PM  
Aug-10-20 07:15AM  
Jul-20-20 10:17AM  
Jul-10-20 03:19PM  
Jul-02-20 01:56PM  
Jun-27-20 11:55AM  
Jun-26-20 02:32PM  
Jun-24-20 06:45AM  
Jun-18-20 10:50PM  
Jun-05-20 06:01AM  
Jun-04-20 07:00AM  
May-29-20 09:10AM  
May-27-20 11:45AM  
May-22-20 09:05AM  
May-21-20 02:44PM  
Apr-28-20 03:44PM  
Apr-27-20 04:15PM  
Apr-24-20 07:00AM  
Apr-09-20 07:30AM  
Apr-03-20 05:01AM  
Mar-26-20 04:20PM  
Mar-20-20 11:38AM  
Mar-18-20 08:00AM  
Mar-13-20 08:08AM  
Mar-12-20 04:45PM  
Mar-05-20 04:20PM  
Mar-02-20 04:30PM  
Feb-28-20 10:12AM  
Feb-17-20 08:52AM  
Feb-06-20 04:30PM  
Feb-04-20 08:54AM  
Feb-03-20 04:15PM  
Jan-16-20 08:00AM  
Jan-06-20 09:15AM  
Dec-23-19 09:30AM  
Dec-19-19 11:22AM  
Dec-16-19 04:15PM  
Dec-13-19 05:00PM  
Dec-10-19 04:44PM  
Dec-03-19 12:31PM  
Dec-02-19 04:15PM  
Oct-25-19 08:30AM  
Oct-22-19 04:30PM  
Sep-19-19 01:58PM  
Sep-17-19 04:15PM  
Aug-26-19 05:30PM  
Aug-21-19 12:15PM  
Aug-19-19 04:35PM  
Jul-25-19 11:16AM  
Jun-19-19 08:00AM  
Jun-10-19 01:58PM  
Jun-03-19 08:00AM  
Apr-24-19 02:03PM  
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Eastern Capital LTD10% OwnerAug 11Sale2.9215,864,43646,330,4998,629,693Aug 11 05:08 PM
Eastern Capital LTD10% OwnerAug 10Sale3.917,264,86428,429,59224,494,129Aug 11 05:08 PM
Eastern Capital LTD10% OwnerAug 07Sale3.831,355,6045,185,59231,758,993Aug 11 05:08 PM
Eastern Capital LTD10% OwnerAug 06Sale4.182,768,13711,570,53633,114,597Aug 06 05:33 PM
Eastern Capital LTD10% OwnerAug 05Sale4.46900,0004,013,55035,882,734Aug 06 05:33 PM
Eastern Capital LTD10% OwnerAug 04Sale4.39600,0002,636,64036,782,734Aug 06 05:33 PM
ERWIN ROBERT LPresidentJun 04Option Exercise0.9328,26826,289108,108Jun 08 12:41 PM
ERWIN ROBERT LPresidentJun 04Sale1.7128,26848,338108,108Jun 08 12:41 PM
ERWIN ROBERT LPresidentJun 02Option Exercise0.9396,12489,395136,376Jun 05 06:04 AM
ERWIN ROBERT LPresidentJun 02Sale1.6296,124155,721136,376Jun 05 06:04 AM
Mullaney James P.Chief Financial OfficerMay 27Option Exercise0.9311,25010,4630May 29 12:45 PM
Mullaney James P.Chief Financial OfficerMay 27Sale1.6111,25018,1130May 29 12:45 PM